Beam Therapeutics Inc. (BEAM) vs Supernus Pharmaceuticals, Inc. (SUPN)
A side-by-side comparison of Beam Therapeutics Inc. and Supernus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BEAM
Beam Therapeutics Inc.
$25.23HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SUPN
Supernus Pharmaceuticals, Inc.
$42.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BEAM vs SUPN
growth of $100 · dividends reinvested · last 7yBEAM +30.7% (+3.9%/yr)SUPN +82.4% (+9.0%/yr)SUPN compounded faster over this window
BEAM SUPN
BEAM vs SUPN: by the numbers
- •BEAM is the larger company ($2.60B vs $2.49B market cap).
- •Both run net losses; SUPN's is the smaller (-13.23% vs -54.75% net margin).
- •BEAM grew revenue faster over the past five years (479.04% vs 7.78% CAGR).
Metrics side by side
Valuation
| Metric | BEAM | SUPN |
|---|---|---|
| Forward P/E | N/A | 16.70 |
| P/S ratio | 16.63 | 2.99 |
| P/B ratio | 2.43 | 2.41 |
| FCF yield | N/A | 0.76% |
Profitability
| Metric | BEAM | SUPN |
|---|---|---|
| Gross margin | 84.05% | 88.07% |
| Operating margin | -274.57% | -5.13% |
| Net margin | -54.75% | -13.23% |
| ROE | -8.00% | -10.66% |
| ROIC | -28.96% | -10.24% |
Growth (annualized)
| Metric | BEAM | SUPN |
|---|---|---|
| Revenue CAGR (5Y) | 479.04% | 7.78% |
| FCF CAGR (5Y) | N/A | -30.77% |
| Total return CAGR (5Y) | -21.36% | 9.85% |
Frequently asked
- Which has grown faster, BEAM or SUPN?
- Over the past five years, BEAM grew revenue faster — BEAM at a 479.04% CAGR versus SUPN at 7.78%.
- How have BEAM and SUPN total returns compared?
- Over the past 5 years, BEAM delivered -21.36% and SUPN delivered 9.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Beam Therapeutics ROESupernus Pharmaceuticals ROEBeam Therapeutics operating marginSupernus Pharmaceuticals operating marginBeam Therapeutics revenue growthSupernus Pharmaceuticals revenue growthBeam Therapeutics free cash flowSupernus Pharmaceuticals free cash flow
Beam Therapeutics & Supernus Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.